JP2021511326A5 - - Google Patents

Info

Publication number
JP2021511326A5
JP2021511326A5 JP2020539792A JP2020539792A JP2021511326A5 JP 2021511326 A5 JP2021511326 A5 JP 2021511326A5 JP 2020539792 A JP2020539792 A JP 2020539792A JP 2020539792 A JP2020539792 A JP 2020539792A JP 2021511326 A5 JP2021511326 A5 JP 2021511326A5
Authority
JP
Japan
Prior art keywords
mtg
monothioglycerol
ascorbic acid
acid
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014422 external-priority patent/WO2019144079A1/en
Publication of JP2021511326A publication Critical patent/JP2021511326A/ja
Publication of JP2021511326A5 publication Critical patent/JP2021511326A5/ja
Pending legal-status Critical Current

Links

JP2020539792A 2018-01-22 2019-01-21 ブプレノルフィンの徐放送達のための薬学的組成物 Pending JP2021511326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620317P 2018-01-22 2018-01-22
US62/620,317 2018-01-22
PCT/US2019/014422 WO2019144079A1 (en) 2018-01-22 2019-01-21 Pharmaceutical composition for sustained release delivery of buprenorphine

Publications (2)

Publication Number Publication Date
JP2021511326A JP2021511326A (ja) 2021-05-06
JP2021511326A5 true JP2021511326A5 (cg-RX-API-DMAC7.html) 2022-01-31

Family

ID=67301573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539792A Pending JP2021511326A (ja) 2018-01-22 2019-01-21 ブプレノルフィンの徐放送達のための薬学的組成物

Country Status (9)

Country Link
US (1) US11419866B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743072B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021511326A (cg-RX-API-DMAC7.html)
CN (1) CN112236142A (cg-RX-API-DMAC7.html)
AU (1) AU2019209416A1 (cg-RX-API-DMAC7.html)
CA (1) CA3089114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2965836T3 (cg-RX-API-DMAC7.html)
TW (1) TW201936191A (cg-RX-API-DMAC7.html)
WO (1) WO2019144079A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091612B1 (en) * 2020-01-14 2025-11-12 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
CN113117092A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 一种非水缓释递药系统
EP4294367A4 (en) * 2021-02-18 2025-02-12 Navin Saxena Research and Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CA3260542A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine, its preparation process, and its use.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
EP1554290B1 (en) 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
CN1263760C (zh) 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
EP2262367A4 (en) 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2009148503A2 (en) 2008-05-30 2009-12-10 Namedepot.Com, Inc. Method and system for providing online services and software
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9168251B2 (en) * 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
US9918981B2 (en) * 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations

Similar Documents

Publication Publication Date Title
JP2017048194A5 (cg-RX-API-DMAC7.html)
JP2018127649A5 (cg-RX-API-DMAC7.html)
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
JP2012107014A5 (cg-RX-API-DMAC7.html)
JP2008527066A5 (cg-RX-API-DMAC7.html)
JP2016505044A5 (cg-RX-API-DMAC7.html)
JP2019518874A5 (cg-RX-API-DMAC7.html)
JP2010520851A5 (cg-RX-API-DMAC7.html)
EP3891240A4 (en) ADHESIVE COMPOSITIONS CONTAINING 1,4-CYCLOHEXANDIMETHANOL AND PROCESS FOR THEIR PREPARATION
HK1217295A1 (zh) 4'-疊氮基,3'-脫氧基-3'-氟取代的核苷衍生物
JP2010053122A5 (cg-RX-API-DMAC7.html)
CN115867545A8 (zh) 抗病毒素1,3-二氧代茚化合物
JP2019218304A5 (cg-RX-API-DMAC7.html)
JP2008540542A5 (cg-RX-API-DMAC7.html)
JP2015193834A5 (cg-RX-API-DMAC7.html)
JP2009532412A5 (cg-RX-API-DMAC7.html)
WO2007101546A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften enthaltend phtalsäurediamidderivaten
BRPI0607652A2 (pt) acil hidrazidas como inibidoras de quinase, em particular para sgk
JP2017014205A5 (cg-RX-API-DMAC7.html)
JP2012522826A5 (cg-RX-API-DMAC7.html)
EP3369816A4 (en) COMPOSITION WITH STABLE INGREDIENT NUCLEIC ACID MOLECULE PRESSING THE EXPRESSION OF THE TGF-BETA1 GENE
JP2007523200A5 (cg-RX-API-DMAC7.html)
FR2916443B1 (fr) Nouveaux derives analogues de l'herbimycine a, compositions les contenant et utilisation.
JP2009538982A5 (cg-RX-API-DMAC7.html)
JP2006298808A5 (cg-RX-API-DMAC7.html)